

Despite advances in treatment, glioblastoma (GBM) remains one of the most difficult types of cancer to treat, and the prognosis is poor. The current median survival time for patients with GBM is about 12-15 months, and the five-year survival rate is less than 10%. There is an unmet need for better GBM treatment options, leveraged from relevant experimental models. To develop new therapies, preclinical animal models are important for analyzing the biology of GBM and evaluating the efficacy of novel therapeutic strategies. While a variety of experimental models are used to study GBM, most preclinical investigations involve mice. In this study we utilize a spatial phenotyping application that permits comprehensive characterization and comparison of key proteins in the brain tumor immune microenvironment (TiME) of the mouse GL261 GBM model of GBM.

DNA-tagged antibodies.



The **PhenoCycler-Fusion** workflow consists of iterative cycles of labelling, imaging and removing fluorescent reporters. In each imaging cycle, three fluorescent reporters are attached to their corresponding DNAtagged antibodies and imaged via standard fluorescent optics. Thereafter, the three reporters are removed, and a new cycle images additional reporters. The process is fully automated, and data are acquired across whole slides at single-cell resolution. Barcoded antibody technology enables deep spatial phenotyping, combining antibody specificity with molecular barcodes to simultaneously detect 100+ targets at high spatial resolution, preserving tissue integrity.



## **3763: Comparative Spatial Analyses of the Tumor Immune Landscape** in Different Mouse Models of Glioblastoma

Dmytro Klymyshyn<sup>1</sup>, Aditya Pratapa<sup>1</sup>, Nadezhda Nikulina<sup>1</sup>, Tsz H.Tam<sup>1</sup>, James DeRosa<sup>1</sup>, Ritu Mihani<sup>1</sup>, Niyati Jhaveri<sup>1</sup>, Nadine Nelson<sup>2</sup>Riccardo Dolcetti<sup>3,4</sup>, Davide Moi<sup>3</sup>, Roberta Mazzieri<sup>3</sup>, Theo Mantamadiotis<sup>4,5</sup>

<sup>1</sup>Akoya Biosciences, Menlo Park, USA; <sup>2</sup>Abcam, Cambridge, UK ; <sup>3</sup>Peter MacCallum Cancer Centre, Australia; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery (RMH), The University of Melbourne, Australia ; <sup>4</sup>Department of Surgery ; <sup>4</sup>Departmen

Akoya Biosciences, Inc., 100 Campus Drive, 6<sup>th</sup> Floor, Marlborough 01752, MA USA (855) 896-8401 <u>www.akoyabio.com</u> For Research Use Only